Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Nexgel (NXGL) EBT (2018 - 2025)

Nexgel (NXGL) has disclosed EBT for 8 consecutive years, with -$647000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT rose 14.19% year-over-year to -$647000.0, compared with a TTM value of -$2.8 million through Sep 2025, up 27.06%, and an annual FY2024 reading of -$3.5 million, down 8.63% over the prior year.
  • EBT was -$647000.0 for Q3 2025 at Nexgel, down from -$640000.0 in the prior quarter.
  • Across five years, EBT topped out at -$552000.0 in Q3 2023 and bottomed at -$1.8 million in Q1 2022.
  • Average EBT over 5 years is -$936789.5, with a median of -$825000.0 recorded in 2024.
  • The sharpest move saw EBT plummeted 161.09% in 2021, then surged 63.29% in 2022.
  • Year by year, EBT stood at -$1.8 million in 2021, then soared by 63.29% to -$648000.0 in 2022, then tumbled by 83.18% to -$1.2 million in 2023, then surged by 30.5% to -$825000.0 in 2024, then rose by 21.58% to -$647000.0 in 2025.
  • Business Quant data shows EBT for NXGL at -$647000.0 in Q3 2025, -$640000.0 in Q2 2025, and -$678000.0 in Q1 2025.